Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.
Miyaji KT, Ibrahim KY, Infante V, Moreira RM, Santos CFD, Belizário JC, Pinto MIM, Marinho AKBB, Pereira JM, Mello LS, Silva VGLD, Sato PK, Strabelli TMV, Ragiotto L, Pacheco PHTM, Braga PE, Loch AP, Precioso AR, Sartori AMC; Study Group; França JÍ, Lima MA, Ando MCS, Rodrigues CCM, Song ATW, Lara AN, Belizário AC, Lima AHSB, Zanetti ACB, Paulo ARDSA, Rosa BMDS, Moraes BDGC, Oliveira BR, Picone CM, Aranda CS, Troli CP, Kokron CM, Terrabuio DRB, Abdala E, David Neto E, Nakanishi ÉYS, Lima FMS, Firmino FB, Santos FBAD, Bacal F, Fatobene G, Santana JO, Kalil J, Barbosa J, Gonçalves LP, Otuyama LJ, Pierrotti LC, Compte LCM, Marinho L, Chaer LN, Seguro LF, Azevedo LS, Ueda MA, Terreri MT, Barros MAMT, Grecco O, Sejas ONE, Musqueira PT, Ito RKL, Teixeira SSS, Fidalgo S, Costa SF, Campos SV, Fernandes TH, Rocha VG, Coelho VC.
Miyaji KT, et al. Among authors: santos cfd.
Rev Inst Med Trop Sao Paulo. 2025 Jan 20;67:e2. doi: 10.1590/S1678-9946202567002. eCollection 2025.
Rev Inst Med Trop Sao Paulo. 2025.
PMID: 39841781
Free article.
Clinical Trial.
